Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047762 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00047762 is a Phase 1 study that has completed, run by Genentech.
The verdict
NCT00047762, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
Interventions
- DRUG Erlotinib (aka Tarceva or OSI-774)
- DRUG Bevacizumab (aka Avastin or Rhu MAb VEGF)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047762
The ClinicalTrials.gov registry entry for NCT00047762 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib (aka Tarceva or OSI-774) is the first listed.
NCT00047762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047762 about?
NCT00047762 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer". The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
What is the current status of trial NCT00047762?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-10.
What interventions are being tested in trial NCT00047762?
The interventions under investigation include: Erlotinib (aka Tarceva or OSI-774) (DRUG), Bevacizumab (aka Avastin or Rhu MAb VEGF) (DRUG).
Who is sponsoring clinical trial NCT00047762?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.